-
181
-
182
-
183
-
184
-
185
-
186
-
187
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management [Corrigendum]
Published 2022-07-01Subjects: Get full text
Article -
188
Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease
Published 2018-01-01Subjects: “…biologics…”
Get full text
Article -
189
-
190
Biologics in Psoriasis: Updated Perspectives on Long-Term Safety and Risk Management
Published 2022-01-01Subjects: Get full text
Article -
191
Latent Tuberculosis in Psoriasis Patients on Biologic Therapies: Real-World Data from a Care Center in Romania
Published 2023-05-01Subjects: Get full text
Article -
192
Managing pediatric psoriasis: update on treatments and challenges—a review
Published 2022-07-01Subjects: Get full text
Article -
193
Use of Mepolizumab in Children and Adolescents with Asthma in the USA
Published 2022-07-01Subjects: Get full text
Article -
194
-
195
Disease response and patient-reported outcomes among initiators of ixekizumab
Published 2022-04-01Subjects: “…biologics…”
Get full text
Article -
196
Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series
Published 2022-05-01Subjects: “…biologics…”
Get full text
Article -
197
Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series
Published 2022-09-01Subjects: Get full text
Article -
198
Successful Treatment of an Adult with Atopic Dermatitis and Lamellar Ichthyosis Using Dupilumab
Published 2022-06-01Subjects: Get full text
Article -
199
-
200
Effect of Biologics on the Need for Procedural Interventions, Systemic Medications, and Healthcare Utilization in Patients with Hidradenitis Suppurativa: Real-World Data from the UNITE Registry
Published 2023-06-01Subjects: “…Biologics…”
Get full text
Article